Abstract
Background A 48-year-old man with a recent diagnosis of multiple myeloma and rapidly progressive oliguric end-stage renal disease requiring hemodialysis, presented with a serum calcium concentration of 3.4 mmol/l (13.6 mg/dl).
Investigations Serum laboratory analysis, electroencephalogram, MRI of the brain and bone marrow, and kidney biopsies.
Diagnosis Hypercalcemia secondary to multiple myeloma.
Management Short-term intravenous disodium pamidronate therapy (30 mg daily) and daily monitoring of serum calcium concentration.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Barri YM et al. (1996) Hypercalcemia and electrolyte disturbances in malignancy. Hematol Oncol Clin North Am 10: 775–790
Pearce CJ et al. (1991) Hypercalcemia due to calcium binding by a polymeric IgA Kappa paraprotein. Ann Clin Biochem 28: 229–234
Ratcliffe WA et al. (1992) Role of assays for parathyroid-hormone-related protein in the investigation of hypercalcaemia. Lancet 339: 164–167
Strewler GJ (2000) The physiology of parathyroid hormone-related protein. N Engl J Med 342: 177–185
Rajkumar V and Kyle R (2005) Multiple myeloma: diagnosis and treatment. Mayo Clinic Proc 80: 1371–1382
Glass DA et al. (2003) A new insight into the formation of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2479–2480
Scheinman SJ et al. (1991) Hypercalcemia with excess serum 1,25 dihydroxyvitamin D in lymphomatoid granulomatosis/angiocentric lymphoma. Am J Med Sci 301: 178–181
Popovtzer M et al. (1992) Disorders of calcium, phosphorus, vitamin D, and parathyroid hormone activity. In Renal and Electrolyte Disorders, edn 4, 287–369 (Ed. Schrier R) Boston: Little, Brown and Company
Rodan GA and Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97: 2692–2696
Fleisch HA (1998) Bisphosphonates: mechanism of action. Endoc Rev 19: 80–100
Markowitz G et al. (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12: 1164–1172
Lu KC et al. (2003) Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 42: 1221–1227
Torregrosa JV et al. (2003) Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. Kidney Int 63 (Suppl): S88–S90
Major PP and Cook R (2002) Efficacy of bisphosphonates in the management of skeletal complications of bone metastasis and selection of clinical endpoints. Am J Clin Oncol 25 (Suppl 1): S10–S18
Lindberg J and Moe S (1999) Osteoporosis in end-state renal disease. Semin Nephrol 19: 115–122
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Trimarchi, H., Lombi, F., Forrester, M. et al. Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient. Nat Rev Nephrol 2, 459–463 (2006). https://doi.org/10.1038/ncpneph0248
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneph0248
This article is cited by
-
Metabolische Entgleisungen als paraneoplastische Syndrome
Der Internist (2018)
-
Reversal of hypercalcemic acute kidney injury by treatment with intravenous bisphosphonates
Pediatric Nephrology (2009)